Recurrencia y características clínico patológicas en los grupos de riesgo establecidos por Oncotype Dx, original y TAILORx, en cáncer de mama temprano-Reference-Cited by-同舟云学术

Recurrencia y características clínico patológicas en los grupos de riesgo establecidos por Oncotype Dx, original y TAILORx, en cáncer de mama temprano

Published:2021 Issue:4 Volume:66 Page:263-272
ISSN:0185-3252
Container-title:Anales Médicos de la Asociación Médica del Centro Médico ABC
language:es
Short-container-title:

Author:

Amador García Geovani,Andrade Moreno Raúl Alejandro,Martínez Herrera José Fabián,Cwilich Raquel Gerson,Serrano Olvera Juan Alberto

Publisher

GRAPHIMEDIC SA DE CV

Reference28 articles.

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71 (3): 209-249. doi: 10.3322/caac.21660.

2. American Cancer Society. Breast Cancer Facts & Figures 2019-2020. Atlanta: American Cancer Society, Inc, 2019. [Consulted 26 February 2021] Available in: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2019-2020.pdf

3. Walks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019; 321 (3): 288-300.

4. Kim EJ, Park HS, Kim JY, Kim SI, Cho YU, Park BW. Assessment of the Prognostic Staging System of American Joint Committee on Cancer 8th Edition for Breast Cancer: Comparisons with the Conventional Anatomic Staging System. J Breast Cancer. 2020; 23 (1): 59-68.

5. Davies C, Godwin J, Gray R, Clarke M, Darby S, McGale P et al. Early Breast Cancer Trialists\\\' Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011; 378: 771-784.